Stefanie Hennig

List of Publications by Year
in descending order

68	1,178	430442 18	433756 31
papers	citations	h-index	g-index

71	71	71	1530
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatric Respiratory Reviews, 2016, 20, 55-66.	1.2	77
2	Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 62-70.	1.0	70
3	Improved prediction of tacrolimus concentrations early after kidney transplantation using theoryâ€based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 2014, 78, 509-523.	1.1	67
4	PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool. Computer Methods and Programs in Biomedicine, 2012, 108, 789-805.	2.6	61
5	Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis. Clinical Pharmacokinetics, 2013, 52, 289-301.	1.6	59
6	Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis â€“ a population pharmacokinetic study. British Journal of Clinical Pharmacology, 2008, 65, 502-510.	1.1	58
7	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. Clinical Pharmacokinetics, 2006, 45, 1099-1114.	1.6	54
8	A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology, 2007, 63, 438-450.	1.1	45
9	Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 521-545.	0.8	38
10	Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6698-6702.	1.4	33
11	Aspergillus and progression of lung disease in children with cystic fibrosis. Thorax, 2019, 74, 125-131.	2.7	32
12	Comparing Dosage Adjustment Methods for Once-Daily Tobramycin in Paediatric and Adolescent Patients with Cystic Fibrosis. Clinical Pharmacokinetics, 2015, 54, 409-421.	1.6	31
13	Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. Clinical Pharmacokinetics, 2020, 59, 1357-1392.	1.6	29
14	An evaluation of the userâ€friendliness of Bayesian forecasting programs in a clinical setting. British Journal of Clinical Pharmacology, 2019, 85, 2436-2441.	1.1	27
15	Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 3407-3414.	1.4	26
16	Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw461.	1.3	26
17	Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. Clinical Pharmacokinetics, 2021, 60, 17-51.	1.6	23
18	A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis. Biomedical Chromatography, 2006, 20, 343-348.	0.8	20

#	Article	IF	Citations
19	Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?. Clinical Pharmacokinetics, 2019, 58, 389-399.	1.6	20
20	Quantitative determination of the enantiomers of methadone in human plasma and saliva by chiral column chromatography coupled with mass spectrometric detection. Talanta, 2016, 149, 142-148.	2.9	19
21	Safety of inhaled (TobiÂ®) and intravenous tobramycin in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 428-434.	0.3	17
22	A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
23	Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis. Clinical Pharmacokinetics, 2018, 57, 1017-1027.	1.6	17
24	Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin. Journal of Clinical Pharmacology, 2012, 52, 347-360.	1.0	16
25	Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the UK. Journal of Pharmacy Practice and Research, 2016, 46, 15-21.	0.5	15
26	Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis. Thorax, 2019, 74, 740-748.	2.7	15
27	Quizzing for success: Evaluation of the impact of feedback quizzes on the experiences and academic performance of undergraduate students in two clinical pharmacokinetics courses. Currents in Pharmacy Teaching and Learning, 2019, 11, 742-749.	0.4	15
28	Successful treatment of Epsteinâ€“Barr virusâ€“associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epsteinâ€“Barr virusâ€“specific T cells. American Journal of Transplantation, 2021, 21, 3465-3471.	2.6	13
29	Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 617-620.	1.4	12
30	Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes. Pediatric Infectious Disease Journal, 2018, 37, 349-355.	1.1	12
31	Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virusâ€infected children in relation to treatment outcomes. British Journal of Clinical Pharmacology, 2019, 85, 2066-2075.	1.1	11
32	Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI??). Therapeutic Drug Monitoring, 2005, 27, 205-207.	1.0	10
33	Gentamicin Pharmacokinetics and Monitoring in Pediatric Patients with Febrile Neutropenia. Therapeutic Drug Monitoring, 2016, 38, 693-698.	1.0	10
34	Population pharmacokinetic drugâ€“drug interaction pooled analysis of existing data for rifabutin and HIV PIs. Journal of Antimicrobial Chemotherapy, 2016, 71, 1330-1340.	1.3	10
35	Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?. Cancer Chemotherapy and Pharmacology, 2017, 80, 15-25.	1.1	10
36	Comparison of methods to estimate glomerular filtration rate in paediatric oncology patients. Journal of Paediatrics and Child Health, 2018, 54, 141-147.	0.4	10

#	Article	IF	Citations
37	Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies. Journal of Clinical Pharmacology, 2009, 49, 323-335.	1.0	9
38	Population pharmacokinetics of phenytoin in critically ill children. Journal of Clinical Pharmacology, 2015, 55, 355-364.	1.0	9
39	Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation. Cancer Chemotherapy and Pharmacology, 2021, 88, 379-391.	1.1	9
40	Comparison of Dose-Finding Designs for Narrow-Therapeutic-Index Drugs: Concentration-Controlled vs. Dose-Controlled Trials. Clinical Pharmacology and Therapeutics, 2009, 86, 62-69.	2.3	8
41	Antimicrobial stewardship in paediatric oncology: Impact on optimising gentamicin use in febrile neutropenia. Pediatric Blood and Cancer, 2018, 65, e26810.	0.8	8
42	Gentamicin Pharmacokinetics and Monitoring in Pediatric Febrile Neutropenic Patients. Therapeutic Drug Monitoring, 2016, , 1.	1.0	8
43	Optimizing disease progression study designs for drug effect discrimination. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 587-596.	0.8	6
44	Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?. Clinical Therapeutics, 2017, 39, 1840-1848.	1.1	6
45	CPT: Pharmacometrics & Systems Pharmacology â€“ Inception, Maturation, and Future Vision. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 649-657.	1.3	6
46	Prediction of glycaemic control in young children and adolescents with type 1 diabetes mellitus using mixed-effects logistic regression modelling. PLoS ONE, 2017, 12, e0182181.	1.1	6
47	Population pharmacokinetic model for onceâ€daily intravenous busulfan in pediatric subjects describing <scp>timeâ€dependent</scp> clearance. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1002-1017.	1.3	6
48	Phenytoin Loading Doses in Adult Critical Care Patients: Does Current Practice Achieve Adequate Drug Levels?. Anaesthesia and Intensive Care, 2013, 41, 602-609.	0.2	5
49	Concordance between criteria for covariate model building. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 109-125.	0.8	5
50	To Cap or Not to Cap: Chemotherapy Dosing in Obese Adult Hematology Patients. Clinical Pharmacology and Therapeutics, 2014, 95, 356-358.	2.3	5
51	Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. Journal of Clinical Pharmacology, 2016, 56, 705-713.	1.0	5
52	Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection. European Journal of Clinical Pharmacology, 2019, 75, 879-888.	0.8	5
53	Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients. AAPS Journal, 2018, 20, 14.	2.2	4
54	Population pharmacokinetic and exploratory exposureâ€“response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer Chemotherapy and Pharmacology, 2021, 88, 499-512.	1.1	4

#	Article	IF	Citations
55	A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data. PLoS ONE, 2016, 11, e0152700.	1.1	4
56	The Influence of Underlying Assumptions on Evaluating the Relative Merits of Concentration-Controlled and Dose-Controlled Trials. Clinical Pharmacology and Therapeutics, 2009, 86, 70-76.	2.3	3
57	Ethically Attractive Doseâ€Finding Designs for Drugs With a Narrow Therapeutic Index. Journal of Clinical Pharmacology, 2012, 52, 29-38.	1.0	3
58	Tacrolimus pharmacokinetics after kidney transplantation â€“ Influence of changes in haematocrit and steroid dose. British Journal of Clinical Pharmacology, 2015, 80, 1475-1476.	1.1	3
59	A systematic review of treatment outcomes with weight-based dosing of chemotherapy in obese adult patients with acute leukemia or lymphoma. Leukemia and Lymphoma, 2016, 57, 981-984.	0.6	3
60	Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	3
61	Pharmacometrics in Australasiaâ€”Twenty Years of Population Approach Group of Australia and New Zealand. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 701-704.	1.3	3
62	Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. British Journal of Clinical Pharmacology, 2021, , .	1.1	3
63	Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosingâ€”A Translational Example for Intensive Care Units. Pharmaceutics, 2021, 13, 2128.	2.0	3
64	Quantitation of the Effect of Azole Antifungals on Tacrolimus Clearance. Journal of Heart and Lung Transplantation, 2016, 35, S236.	0.3	2
65	Comment on â€œEffect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trialsâ€• Clinical Pharmacokinetics, 2018, 57, 1471-1472.	1.6	2
66	Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology, 2022, 88, 403-415.	1.1	2
67	Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. Antibiotics, 2022, 11, 758.	1.5	2
68	What â€œImpactâ€•Do NLME Publications Have Outside Our Community?. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 191-194.	1.3	1